The separation of Ebglyss from Dupixent and Adbry/Adtralza will depend on real-world clinical benefits, patient experience ...
Less frequent dosing could provide Eli Lilly’s Ebglyss room to rival Sanofi and Regeneron’s blockbuster Dupixent.
AbbVie’s immunology duo Skyrizi and Rinvoq is, in a rare blip this year, not leading the pharma DTC monthly rankings as ...
Johnson & Johnson stopped short of implementing its proposal to alter the way two drugs are paid for under the 340B drug discount program, but the drugmaker made it clear it still wants changes. In ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
The label expansion provides a new option for the hundreds of thousands of Americans with inadequately controlled COPD.
The U.S. Food and Drug Administration has approved Regeneron's Dupixent (dupilumab) as an add-on maintenance treatment for ...
The biotech, which has now raised more than $200 million since launch, is advancing an eczema treatment that could start human trials next year.
Triveni Bio has roped in $115 million in series B funds to advance preclinical antibody programs designed to treat ...
The US Food and Drug Administration has approved dupilumab as an add-on maintenance therapy for adults whose chronic ...
The FDA has approved Dupixent (dupilumab) as an add-on therapy for adults with poorly controlled COPD, especially those with ...
RA Capital, RTW Investments, Janus Henderson Investors are pouring another $175 million into a radiopharmaceuticals startup.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback